Kern David M, Zhou Siting, Chavoshi Soheil, Tunceli Ozgur, Sostek Mark, Singer Joseph, LoCasale Robert J
Am J Manag Care. 2015 Mar 1;21(3):e222-34.
To evaluate treatment patterns, healthcare resource utilization, and costs among patients within a large managed care population chronically using opioids for non-cancer pain.
Retrospective cohort study.
Patients aged ≥18 years with ≥1 prescription initiating opioids between January 1, 2007, and December 31, 2011, who also had 12 months of continuous pre-index health plan enrollment, were identified. Patients with pre-index opioid use or cancer diagnosis were excluded. Opioid exposure was stratified by treatment duration-short-term (30-182 days) versus chronic (≥183 days)-and by index opioid type (weak vs strong).
A total of 2.9 million patients initiating opioids were identified, of which 257,602 had at least 30 days of continuous use and were included in the study. The mean age was 51 years and 52% were female. Overall, 239,998 (93%) patients had short-term opioid use, and 17,604 (7%) had chronic use; 215,424 (84%) initiated treatment with a weak opioid, and 44,712 (17%) with a strong opioid. The specialty most associated with the use of less potent opioids was general/family practice (28%), and for more potent opioids it was surgery (22%). Large increases in health-care utilization were reported between the pre-index and first 6-month post initiation periods for chronic users. Utilization rates decreased after the first 6 months but never reverted to baseline levels. Costs mirrored utilization trends, more than doubling between baseline and the first 6 months of treatment for pharmacy ($2029 vs $4331) and all-cause medical ($11,430 vs $27,365). Costs declined after the first 6 months of opioid use but remained above pre-index levels.
These results demonstrated that healthcare resource utilization and costs increased during the first 6 months following clinical scenarios that necessitated opioid initiation and subsequently declined, suggesting the need to monitor patients beyond the acute care period.
评估在一个大型管理式医疗人群中,长期使用阿片类药物治疗非癌性疼痛的患者的治疗模式、医疗资源利用情况及成本。
回顾性队列研究。
确定年龄≥18岁,在2007年1月1日至2011年12月31日期间至少有1张启动阿片类药物处方,且在索引前连续12个月参加健康计划的患者。排除索引前使用阿片类药物或患有癌症诊断的患者。阿片类药物暴露按治疗持续时间分层——短期(30 - 182天)与长期(≥183天)——以及按索引阿片类药物类型(弱效与强效)分层。
共识别出290万启动阿片类药物治疗的患者,其中257,602名患者持续使用至少30天并纳入研究。平均年龄为51岁,52%为女性。总体而言,239,998名(93%)患者短期使用阿片类药物,17,604名(7%)患者长期使用;215,424名(84%)患者开始使用弱效阿片类药物治疗,44,712名(17%)患者使用强效阿片类药物。与使用低效阿片类药物最相关的专科是普通/家庭医学(28%),与使用高效阿片类药物最相关的是外科(22%)。据报告,长期使用者在索引前和启动后的前6个月期间医疗保健利用率大幅增加。6个月后利用率下降,但从未恢复到基线水平。成本反映了利用率趋势,药房(2029美元对4331美元)和全因医疗(11,430美元对27,365美元)在基线和治疗的前6个月之间增加了一倍多。使用阿片类药物6个月后成本下降,但仍高于索引前水平。
这些结果表明,在因临床情况需要启动阿片类药物治疗后的前6个月内,医疗资源利用和成本增加,随后下降,这表明需要在急性治疗期之后对患者进行监测。